Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07261085 · ClinicalTrials.gov registry record
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
A clinical trial of COVID-19, sponsored by Pfizer.
- Active
- Registry status
- 99,000
- Enrollment target
- 1
- Study location
NCT07261085 is a study of COVID-19 that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 99,000 participants, above the 54,727-participant average among 203 other COVID-19 trials with a reported enrollment target (81% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07261085, a study of COVID-19, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 99,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about the effects of the study medicine called Paxlovid \[nirmatrelvir-ritonavir/PF-07321332\], for the potential treatment of COVID-19. This study will use patient health records in Ontario, to find people who were sick with COVID-19 and visited a pharmacist to be treated, anytime from December 1st, 2022, to March 31st, 2024. To be included in our study, the people must be over 18 years of age and be registered in the Ontario health system for at least one year. People were not included in our study if they have been pregnant in the past year or have serious kidney or liver disease. We will separate the people in the study into two groups: those who received treatment with Paxlovid \[nirmatrelvir-ritonavir/PF-07321332\] and those who received no treatment. We will monitor their healthcare visits or if they die for any reason, for up to 60 days after the date that they visited their pharmacist. Then we will compare participant experiences when they are taking the study medicine to when they are not. This will help us determine if the study medicine is effective.
Conditions Studied
Interventions
- OTHER No treatment
- DRUG nirmatrelvir-ritonavir
Study Locations (1)
New York
- Pfizer New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,000 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2026-03-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07261085
The ClinicalTrials.gov registry entry for NCT07261085 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 99,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 54,727-participant average among 203 other COVID-19 trials with a reported enrollment target (81% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which No treatment is the first listed.
NCT07261085 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07261085 about?
NCT07261085 is a clinical study titled "A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.". The purpose of this study is to learn about the effects of the study medicine called Paxlovid \[nirmatrelvir-ritonavir/PF-07321332\], for the potential treatment of COVID-19. This study will use patient health records in Ontario, to find people who were sick with COVID-19 and visited a pharmacist t...
What is the current status of trial NCT07261085?
This trial is currently active not recruiting. The enrollment target is 99,000 participants. The study started on 2025-10-27. Estimated completion is 2026-03-30.
What conditions does trial NCT07261085 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07261085?
The interventions under investigation include: No treatment (OTHER), nirmatrelvir-ritonavir (DRUG).
Who is sponsoring clinical trial NCT07261085?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07261085 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.